1. Home
  2. ALX vs VIR Comparison

ALX vs VIR Comparison

Compare ALX & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alexander's Inc.

ALX

Alexander's Inc.

HOLD

Current Price

$264.59

Market Cap

1.3B

Sector

Real Estate

ML Signal

HOLD

Logo Vir Biotechnology Inc.

VIR

Vir Biotechnology Inc.

HOLD

Current Price

$10.09

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ALX
VIR
Founded
1928
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.5B
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
ALX
VIR
Price
$264.59
$10.09
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$19.43
AVG Volume (30 Days)
20.9K
2.0M
Earning Date
05-04-2026
05-06-2026
Dividend Yield
7.20%
N/A
EPS Growth
N/A
17.49
EPS
0.91
N/A
Revenue
$213,183,000.00
$68,556,000.00
Revenue This Year
N/A
$270.22
Revenue Next Year
N/A
N/A
P/E Ratio
$287.79
N/A
Revenue Growth
N/A
N/A
52 Week Low
$201.28
$4.16
52 Week High
$271.02
$11.66

Technical Indicators

Market Signals
Indicator
ALX
VIR
Relative Strength Index (RSI) 60.65 64.22
Support Level $229.48 $8.40
Resistance Level $271.02 $10.10
Average True Range (ATR) 6.84 0.49
MACD -0.06 0.17
Stochastic Oscillator 75.08 95.30

Price Performance

Historical Comparison
ALX
VIR

About ALX Alexander's Inc.

Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing, and redeveloping its properties. It has five properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City, which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.

About VIR Vir Biotechnology Inc.

Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.

Share on Social Networks: